|
Click here to get the latest updates on the study.
Press Release: WARFARIN Study Launched to Assess Impact of Genetic Testing in Reducing Hospitalizations and Deaths Caused by Warfarin
First major personalized medicine study authorized by Centers for Medicare & Medicaid Services may drive reimbursement based on improved patient safety, reduced healthcare costs.
Bothell, WA, March 1, 2011
- Bothell, WA, March 1, 2011 -- Iverson Genetic Diagnostics, Inc. announced today that the WARFARIN Study (Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation) was initiated in major hospital systems nationwide to assess the utility of genetic testing to determine a personalized warfarin dose for individual patients to reduce their risk of serious bleeding or clotting events. Warfarin, the most commonly prescribed blood thinner worldwide, causes up to 100,000 serious and unnecessary adverse events every year, including th |
